High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02732-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Yuriko Ishida und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka Higashi Kanazawaku, Yokohama, Kanagawa, 236-0051,…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lung Diseases, Interstitial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Interstitial pneumonia (IP) is a common comorbidity with poor prognosis in patients with non-small cell lung cancer (NSCLC) and a risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. This study aimed to assess the incidence, severity, and risk factors of ICI-induced pneumonitis in patients with NSCLC and idiopathic IP. METHODS: This multicenter, retrospective study involved patients with advanced or recurrent NSCLC and comorbid idiopathic IP and receiving ICI monotherapy as the second or subsequent line. A board-certified radiologist centrally reviewed all computed tomography images at baseline and at the onset of pneumonitis. Logistic regression analysis with clinical, laboratory, and radiological variables was used to examine the risk factors for pneumonitis. RESULTS: This study included 65 patients with a median age of 71 years, 98.5% of whom had a smoking history. Three ICIs were used and a median of three cycles. Honeycomb lung was present in 23.1% of the patients, and the median % forced vital capacity (FVC) was 95.0%. Notably, 23.1% of the patients exhibited all-grade pneumonitis and 15.4% exhibited grade ≥ 3 pneumonitis. No significant risk factors for pneumonitis were identified after univariate logistic regression analysis. The incidence and severity of ICI-induced pneumonitis did not differ between patients with and without honeycomb lung or with FVC ≥ 80% versus < 80%, respectively. CONCLUSION: In this retrospective analysis of patients with NSCLC, the risk of ICI-induced pneumonitis did not differ based on radiologic patterns of comorbid IP, presence or absence of honeycomb lung, or pulmonary function tests.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka Higashi Kanazawaku, Yokohama, Kanagawa, 236-0051, Japan.
- Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka Higashi Kanazawaku, Yokohama, Kanagawa, 236-0051, Japan. isatoshi0112@gmail.com.
- Center for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Hokkaido, Japan.
- Department of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan.
- Department of Respiratory Medicine, Obihiro Kosei Hospital, Obihiro, Hokkaido, Japan.
Zitieren
APA
Ishida, Y., Ikeda, S., Harada, T., Sakakibara-Konishi, J., Yokoo, K., Kikuchi, H., Iwasawa, T., Misumi, T., Konno, S., & Ogura, T. (2025). High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02732-2
Vancouver
Ishida Y, Ikeda S, Harada T, Sakakibara-Konishi J, Yokoo K, Kikuchi H, et al. High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02732-2
BibTeX
@article{Ishida2025,
author = {Ishida, Yuriko and Ikeda, Satoshi and Harada, Toshiyuki and Sakakibara-Konishi, Jun and Yokoo, Keiki and Kikuchi, Hajime and Iwasawa, Tae and Misumi, Toshihiro and Konno, Satoshi and Ogura, Takashi},
title = {High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02732-2}
}
EUVIMED